Form 4: Co-Diagnostics, Inc. (CODX), Murphy Ted, transaction 01/08/2022

Summary

A Form 4 filed with the Securities and Exchange Commission by Edward L. Murphy, a director of Co-Diagnostics, Inc. (CODX). It reports the vesting on 01/08/2022 of 12,500 restricted stock units, converted into an equal number of common shares, after which the reporting person owned 25,000 shares directly. The explanation of responses says the units came from 37,500 awarded to the reporting person on January 8, 2021 under the issuer's 2015 Long Term Incentive Plan, with three equal installments vesting every twelve months, and Table II shows 12,500 units still unvested. The form is signed /s/ Edward L. Murphy and dated 01/10/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * MURPHY TED (Last) (First) (Middle) 2401 S. FOOTHILL DRIVE SUITE D (Street) SALT LAKE CITY UT 84109 (City) (State) (Zip) | MURPHY TED | (Last) | (First) | (Middle) | 2401 S. FOOTHILL DRIVE SUITE D | SALT LAKE CITY | UT | 84109 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Co-Diagnostics, Inc. [ CODX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 01/08/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 01/08/2022 | A | 12,500 | A | $ 0.00 | 25,000 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Units | $ 0.00 | 01/08/2022 | M | 12,500 | (1) | (1) | Common Stock | 25,000 | $ 0.00 | 12,500 | D
Explanation of Responses:
1. Included in 37,500 restricted stock units awarded to the Reporting Person on January 8, 2021, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in three equal installments every twelve months commencing on January 8, 2021.
Remarks:
/s/ Edward L. Murphy | 01/10/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_CODX_4_filed2022-01-10_0001562180-22-000368.xml

Size

16,267 bytes

SHA-256

1fcc2c177241a5c683a9c6c9a887e98f670dda2f7d04e3949f2f28ddb9d6e832

Our copy

SEC_CODX_4_filed2022-01-10_0001562180-22-000368.xml

Original

www.sec.gov